National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 21, 2009 • Volume 6 / Number 8

The information and links on this page are no longer being updated and are provided for reference purposes only.

FDA Update

GSK Seeks Approval for HPV Vaccine

Cervarix human papillomavirus vaccine Last month, GlaxoSmithKline (GSK) submitted final data from a phase III study of its cervical cancer vaccine Cervarix to the FDA in a Biologics License Application (BLA).

The study, HPV-008, involved 18,600 women aged 15 to 25 years from 14 countries in Europe, Asia, and Latin and North America. According to a news release issued by the company, GSK will submit the data included in the BLA “to a peer-reviewed journal in the coming months.”   

BLA reviews are typically conducted within 6 months, GSK noted in the news release. If approved, Cervarix would be the second HPV vaccine available in the United States. Gardasil, manufactured by Merck, was approved in 2006.